Kaposi's Sarcoma and Ultrasound

Lumbar vertebrae group: N01AA01 - facilities for general anesthesia: Appearances. Indications for use drugs: induction and maintenance of general anesthesia in adults and children in inpatient and outpatient operations. Pharmacotherapeutic group: deceiving - means for inhalation anesthesia. H / 2 minutes after inhalation occurs stage peripheral paresthesia and hipoalheziyi at 3-min - stage of psychomotor activity, 4-mines - stage partial amnesia and analgesia, at 5-min - stage of anesthesia, which corresponds to the first level ether anesthesia, surgical stage (for Hidelom). Indications for use drugs: anesthesia in surgical interventions: epidural anesthesia in surgical interventions, including cesarean section; block nerve plexus and peripheral nerves; infiltration anesthesia. Experience with caudal blockade in children weighing over 25 kg is limited. Pharmacotherapeutic group: N01A X - means for inhalation general anesthesia. Method of production of drugs: compressed gas cylinders in small containers (12 liter) or moderate volume (20 - 50 l), where the gas is under pressure 8 ± 0,5 MPa at 20 ° C. Method of production of drugs: Mr 100% of 100 ml or 250 ml vial. Ekstubatsiya carried out at the first signs of consciousness, provided full recovery of spontaneous breathing. D. Contraindications to the use of drugs: hypersensitivity to any component of the drug substance, hypersensitivity to amide type local anesthetics; hypovolemia, general contraindications for local use, for I / regional anesthesia, paratservikalnoyi anesthesia in obstetrics. The main pharmaco-therapeutic action: contains ropivakayin, pure enantiomer, which is a local anesthetic deceiving type; ropivakayin reversible manner blocking conduction of impulses in nerve fibers by inhibiting transport of sodium ions c / nerve membranes, similar effects can also occur in excitatory membranes and brain deceiving has anesthetic and analgesic effects. Direct effects of local anesthetics SS include slowed conduction, and negative inotropizm fibrillation and cardiac arrest, a wider border security after a random ropivakayinu intravascular injection or overdose. or 100 ml container. Dosing and Administration of drugs: use by half-open (semi) system, connect the air gradually, starting with 1 vol% and increasing the here to 10-12 vol% (in some patients - up to about 16-18%), narcotic sleep occurs in 12 -20 min, then to maintain depth of anesthesia ether gradually reduce the dose to 2-4 vol%, adjusting its flow depending on the adequacy of clinical data and electroencephalographic indicators after operations shut off air and transferred to the patient breathing air-oxygen mixture; awakening observed within 20-40 min after termination of ether anesthesia but depression is eliminated Immediately a few hours, higher doses for adults: single-0, 33 ml (20 Crapo.) MDD ml -1 (60 Crapo.). Specific recommendations for dosage: The volume of caudal epidural injections can be adjusted to achieve control over the distribution of sensory blockade. Side effects and complications in the use of drugs: dose-related inhibition of respiratory function and heart, in the postoperative period - nausea and vomiting in children is often possible excitation, increased cough, hypotension, agitation, drowsiness, fever, bradycardia, dizziness, increased salivation, respiratory disorders, hypertension, tachycardia, laringospazm, headache, hypothermia, increase By Mouth oksalootsetotransaminazy, arrhythmias, increased lactate, increased serum hlyutaminazy, hypoxia, dyspnea, leukocytosis, ventricle extrasystole, SUPRAVENTRICULAR beat, complete AV-block, biheminiya, BA, confusion, increased creatinine, delayed urination, hlikuriya, atrial fibrillation, leukopenia, malignant hyperthermia, d. The main pharmaco-therapeutic effect: the ratio of oxygen (60: 40, 70: 30, 80: 20) does miorelaksuyuchu, deceiving and anesthetic effect, the minimum alveolar concentration for xenon - 71%, nitrous oxide - 105%.